Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion type Assertion NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_head.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion evidence source_evidence_literature NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion SIO_000772 20080466 NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion wasDerivedFrom befree-2016 NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.
- NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion wasGeneratedBy ECO_0000203 NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.